Frontiers in Immunology · 2021 · 25 citations · 73 references
Life SciencesImmunologyPharmaceuticsAutoimmunityDrug DeliveryNanoparticle Drug DeliveryAutoantigensAutoimmune DiseasesDendritic Cell BiologyNanocarriers For TherapeuticsNanoparticle-based ImmunotechnologyRegulation Of AutoimmunityImmunosuppressive CompoundsImmunosuppressive MicroenvironmentMicroparticle Delivery SystemsMicroparticle FormulationsNanoparticle-based Immune ToleranceNanoparticle-based ImmunotherapyTolerogenic Dendritic Cell TherapyType 1 Diabetes Pathophysiology
Type 1 diabetes (T1D) is a disorder of impaired glucoregulation due to lymphocyte-driven pancreatic autoimmunity. Mobilizing dendritic cells (DC) in vivo to acquire tolerogenic activity is an attractive therapeutic approach as it results in multiple and overlapping immunosuppressive mechanisms. Delivery of agents that can achieve this, in the form of micro/nanoparticles, has successfully prevented a number of autoimmune conditions in vivo . Most of these formulations, however, do not establish multiple layers of immunoregulation. all- trans retinoic acid (RA) together with transforming growth factor beta 1 (TGFβ1), in contrast, has been shown to promote such mechanisms. When delivered in separate nanoparticle vehicles, they successfully prevent the progression of early-onset T1D autoimmunity in vivo . Herein, we show that the approach can be simplified into a single microparticle formulation of RA + TGFβ1 with surface decoration with the T1D-relevant insulin autoantigen. We show that the onset of hyperglycemia is prevented when administered into non-obese diabetic mice that are at the mid-stage of active islet-selective autoimmunity. Unexpectedly, the preventive effects do not seem to be mediated by increased numbers of regulatory T-lymphocytes inside the pancreatic lymph nodes, at least following acute administration of microparticles. Instead, we observed a mild increase in the frequency of regulatory B-lymphocytes inside the mesenteric lymph nodes. These data suggest additional and potentially-novel mechanisms that RA and TGFβ1 could be modulating to prevent progression of mid-stage autoimmunity to overt T1D. Our data further strengthen the rationale to develop RA+TGFβ1-based micro/nanoparticle “vaccines” as possible treatments of pre-symptomatic and new-onset T1D autoimmunity.
73
Reciprocal T <sub>H</sub> 17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
Daniel Mucida, Yunji Park, Gisen Kim et al. · Science · 2007 · 1.9K citations
Five-Year Follow-Up After Clinical Islet Transplantation
Edmond A. Ryan, Breay W. Paty, Peter Senior et al. · Diabetes · 2005 · 1.6K citations · Full text
Medicine, Endocrinology, Surgery +14